Nevertheless, alternative studies have implicated different SIRT2 downstream targets in the regulation of gastric cancer and hepatocellular carcinoma migration [63,64], supporting that SIRT2 inhibition may modulate the migratory capacity of different cancer types via diverse mechanisms. The gene discussed is SIRT2; the disease is cancer.